medigraphic.com
Instituto Nacional de Salud Pública

2022, Número 1

<< Anterior Siguiente >>

salud publica mex 2022; 64 (1)


Mortalidad por cáncer hepático en México: análisis de tendencias de 1998 a 2018

Álvarez CS, Espinosa-Tamez P, López-Ridaura R, Lamadrid-Figueroa H, Melchor-Ruan J, McGlynn KA, Lajous M

Idioma: Ingles.
Referencias bibliográficas: 31
Paginas: 14-25
Archivo PDF: 569.46 Kb.


RESUMEN

Objetivo. Examinar la tendencia general, por sexo y estado, de mortalidad por cáncer hepático en México. Material y métodos. Se utilizó regresión joinpoint para examinar las tendencias en las tasas de mortalidad estandarizadas por edad de cáncer hepático (1998-2018). Se estimó el cambio porcentual anual con intervalos de confianza al 95% (IC95%). Se usaron modelos de edad-periodo-cohorte para evaluar el efecto de edad, año calendario y cohorte de nacimiento. Resultados. La mortalidad osciló entre 3.34 (Aguascalientes) y 7.96 (Chiapas) por 100 000 años-persona. La mortalidad por sexo fue relativamente similar a nivel nacional. La mortalidad general disminuyó entre 1998-2018 (cambio porcentual anual, -0.8%; IC95% -1.0, -0.6). La cohorte de nacimiento parece ser el factor más importante que afecta las tendencias. Conclusiones. A pesar de la disminución de mortalidad por cáncer hepático, se observó variación regional en las tasas. Estas diferencias podrían informar estudios futuros sobre la etiología de cáncer hepático en México.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology. 2021;73(supl 1):4-13. https://doi.org/10.1002/ hep.31288

  2. Ferlay J, Ervik M, Colombet M, Piñeros M, Znaor A, Soerjomataram I, et al. Global Cancer Observatory: Cancer Today [internet]. Lyon: International Agency for Research on Cancer, 2020. Available from: https://gco. iarc.fr/today

  3. Petrick JL, Florio AA, Znaor A, Ruggieri D, Laversanne M, Alvarez CS, et al. International trends in hepatocellular carcinoma incidence, 1978-2012. Int J Cancer. 2020;147(2):317-30. https://doi.org/10.1002/ijc.32723

  4. Wong MC, Jiang JY, Goggins WB, Liang M, Fang Y, Fung FD, et al. International incidence and mortality trends of liver cancer: a global profile. Sci Rep. 2017;7:45846. https://doi.org/10.1038/srep45846

  5. Wallace MC, Preen D, Jeffrey GP, Adams LA. The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert Rev Gastroenterol Hepatol. 2015;9(6):765-79. https://doi.org/10.1586/17474124.2015.1028363

  6. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118-27. https://doi.org/10.1056/NEJMra1001683

  7. Polaris Observatory C. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383-403. https://doi.org/10.1016/S2468- 1253(18)30056-6

  8. Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016;22(34):7824-40. https://doi.org/10.3748/wjg.v22.i34.7824

  9. Barquera S, Rivera JA. Obesity in Mexico: rapid epidemiological transition and food industry interference in health policies. Lancet Diabetes Endocrinol. 2020;8(9):746-7. https://doi.org/10.1016/S2213-8587(20)30269-2

  10. Institute for Health Metrics and Evaluation. GBD Compare Data Visualization [internet]. Seattle: IHME, University of Washington, 2020. Available from: http://vizhub.healthdata.org/gbd-compare

  11. Mendez-Sanchez N, Garcia-Villegas E, Merino-Zeferino B, Ochoa-Cruz S, Villa AR, Madrigal H, et al. Liver diseases in Mexico and their associated mortality trends from 2000 to 2007: A retrospective study of the nation and the federal states. Ann Hepatol. 2010;9(4):428-38.

  12. Torres-Poveda K, Burguete-Garcia AI, Madrid-Marina V. Liver cirrhosis and hepatocellular carcinoma in Mexico: impact of chronic infection by hepatitis viruses B and C. Ann Hepatol. 2011;10(4):556-8.

  13. Mendez-Sanchez N, Villa AR, Vazquez-Elizondo G, Ponciano-Rodriguez G, Uribe M. Mortality trends for liver cancer in Mexico from 2000 to 2006. Ann Hepatol. 2008;7(3):226-9.

  14. Consejo Nacional de Población. Datos Abiertos de México - Proyecciones de la Población de México y de las Entidades Federativas, 2016-2050 [internet]. Ciudad de México: Conapo, 2020. Available from: https://datos. gob.mx/busca/dataset/proyecciones-de-la-poblacion-de-mexico-y-de-lasentidades- federativas-2016-2050

  15. Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJ, Lozano R, Inoue M. Age standardization of rates: A new WHO standard. Geneva: World Health Organization, 2001.

  16. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3):335- 51. https://doi.org/10.1002/(sici)1097-0258(20000215)19:3<335::aidsim336> 3.0.co;2-z

  17. Holford TR, Zhang Z, McKay LA. Estimating age, period and cohort effects using the multistage model for cancer. Stat Med. 1994;13(1):23-41. https://doi.org/10.1002/sim.4780130105

  18. Lin L, Yan L, Liu Y, Qu C, Ni J, Li H. The Burden and Trends of Primary Liver Cancer Caused by Specific Etiologies from 1990 to 2017 at the Global, Regional, National, Age, and Sex Level Results from the Global Burden of Disease Study 2017. Liver Cancer. 2020;9(5):563-82. https://doi. org/10.1159/000508568

  19. Yeverino-Gutierrez ML, Gonzalez-Gonzalez MDR, Gonzalez-Santiago O. Mortality From Alcohol-Related Liver Cirrhosis in Mexico (2000- 2017). Front Public Health. 2020;8:524356. https://doi.org/10.3389/ fpubh.2020.524356

  20. Salvatore M, Jeon J, Meza R. Changing trends in liver cancer incidence by race/ethnicity and sex in the US: 1992-2016. Cancer Causes Control. 2019;30(12):1377-88. https://doi.org/10.1007/s10552-019-01237-4

  21. Escobar ER, Gamino MNB, Salazar RM, Hernandez ISS, Martinez VC, Bautista CF, et al. National trends in alcohol consumption in Mexico: results of the National Survey on Drug, Alcohol and Tobacco Consumption 2016-2017. Salud Ment. 2018;41(1):7-15. https://doi.org/10.17711/ Sm.0185-3325.2018.003

  22. Camarillo EH, Ramirez-Martinez A, Carvajal-Moreno M, Vargas-Ortiz M, Wesolek N, Rodriguez Jimenes GDC, et al. Assessment of Aflatoxin M1 and M2 exposure risk through Oaxaca cheese consumption in southeastern Mexico. Int J Environ Health Res. 2018;28(2):202-13. https://doi.org/10 .1080/09603123.2018.1453054

  23. Castillo-Urueta P, Carvajal M, Mendez I, Meza F, Galvez A. Survey of aflatoxins in maize tortillas from Mexico City. Food Addit Contam Part B Surveill. 2011;4(1):42-51. https://doi.org/10.1080/19393210.20 10.533390

  24. Suarez-Bonnet E, Carvajal M, Mendez-Ramirez I, Castillo-Urueta P, Cortes-Eslava J, Gomez-Arroyo S, et al. Aflatoxin (B1, B2, G1 and G2) contamination in rice of Mexico and Spain, from local sources or imported. J Food Sci. 2013;78(11):T1822-9. https://doi.org/10.1111/1750- 3841.12291

  25. Smith JW, Kroker-Lobos MF, Lazo M, Rivera-Andrade A, Egner PA, Wedemeyer H, et al. Aflatoxin and viral hepatitis exposures in Guatemala: Molecular biomarkers reveal a unique profile of risk factors in a region of high liver cancer incidence. PLoS One. 2017;12(12):e0189255. https://doi. org/10.1371/journal.pone.0189255

  26. Kensler TW, Roebuck BD, Wogan GN, Groopman JD. Aflatoxin: a 50-year odyssey of mechanistic and translational toxicology. Toxicol Sci. 2011;120(supl 1):S28-48. https://doi.org/10.1093/toxsci/kfq283

  27. Agosti P, Sabba C, Mazzocca A. Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment. Biochim Biophys Acta Mol Basis Dis. 2018;1864(2):607-17. https:// doi.org/10.1016/j.bbadis.2017.11.026

  28. Pinto Marques Souza de Oliveira C, Pinchemel Cotrim H, Arrese M. Nonalcoholic Fatty Liver Disease Risk Factors in Latin American Populations: Current Scenario and Perspectives. Clin Liver Dis (Hoboken). 2019;13(2):39-42. https://doi.org/10.1002/cld.759

  29. Meza R, Barrientos-Gutierrez T, Rojas-Martinez R, Reynoso-Noveron N, Palacio-Mejia LS, Lazcano-Ponce E, et al. Burden of type 2 diabetes in Mexico: past, current and future prevalence and incidence rates. Prev Med. 2015;81:445-50. https://doi.org/10.1016/j.ypmed.2015.10.015

  30. Mathers CD, Fat DM, Inoue M, Rao C, Lopez AD. Counting the dead and what they died from: an assessment of the global status of cause of death data. Bull World Health Organ. 2005;83(3):171-7.

  31. Lozano-Esparza S, Stern D, Hernandez-Avila JE, Morales-Carmona E, Mohar A, Lajous M. Evaluation of Mexico’s low cancer mortality using two national death registries. Salud Publica Mex. 2020;62(2):181-5. https://doi. org/10.21149/10635




2020     |     www.medigraphic.com